Total Payments
$9,643
2024 Payments
$2,018
Companies
29
Transactions
533
Medicare Patients
7,151
Medicare Billing
$635,962
Payment Breakdown by Category
Food & Beverage$9,297 (96.4%)
Education$346.41 (3.6%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $9,297 | 528 | 96.4% |
| Education | $346.41 | 5 | 3.6% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $2,146 | 127 | $0 (2024) |
| Janssen Biotech, Inc. | $1,580 | 93 | $0 (2024) |
| Lilly USA, LLC | $1,376 | 67 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $885.95 | 54 | $0 (2024) |
| PFIZER INC. | $655.70 | 33 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $434.00 | 25 | $0 (2024) |
| Amgen Inc. | $330.71 | 18 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $234.19 | 7 | $0 (2024) |
| UCB, Inc. | $210.49 | 9 | $0 (2024) |
| Sun Pharmaceutical Industries Inc. | $203.31 | 9 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $2,018 | 95 | Janssen Biotech, Inc. ($503.47) |
| 2023 | $1,502 | 71 | Janssen Biotech, Inc. ($344.06) |
| 2022 | $995.24 | 55 | ABBVIE INC. ($401.89) |
| 2021 | $1,015 | 70 | AbbVie Inc. ($444.01) |
| 2020 | $553.00 | 29 | AbbVie Inc. ($165.23) |
| 2019 | $1,198 | 68 | Lilly USA, LLC ($203.48) |
| 2018 | $1,245 | 72 | Novartis Pharmaceuticals Corporation ($277.61) |
| 2017 | $1,118 | 73 | Celgene Corporation ($174.73) |
All Payment Transactions
533 individual payment records from CMS Open Payments — Page 22 of 22
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 01/30/2017 | AbbVie, Inc. | Humira (Biological) | Food and Beverage | In-kind items and services | $16.82 | General |
| Category: Immunology | ||||||
| 01/27/2017 | Bayer HealthCare Pharmaceuticals Inc. | Finacea (Drug), Desonate | Food and Beverage | In-kind items and services | $19.24 | General |
| Category: Dermatology | ||||||
| 01/23/2017 | Janssen Biotech, Inc. | STELARA (Biological) | Food and Beverage | In-kind items and services | $16.32 | General |
| Category: Immunology | ||||||
| 01/23/2017 | Janssen Biotech, Inc. | STELARA (Biological) | Food and Beverage | In-kind items and services | $1.44 | General |
| Category: Immunology | ||||||
| 01/20/2017 | Celgene Corporation | — | Food and Beverage | In-kind items and services | $3.50 | General |
| 01/16/2017 | TARO PHARMACEUTICALS USA, INC. | Topicort (Drug) | Food and Beverage | In-kind items and services | $17.10 | General |
| Category: Dermatology | ||||||
| 01/13/2017 | Lilly USA, LLC | TALTZ (Drug) | Food and Beverage | In-kind items and services | $17.21 | General |
| Category: Immunology | ||||||
| 01/03/2017 | Celgene Corporation | — | Food and Beverage | In-kind items and services | $6.05 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 20 | 1,717 | 3,002 | $595,995 | $148,015 |
| 2022 | 22 | 1,977 | 3,433 | $672,048 | $171,431 |
| 2021 | 20 | 1,866 | 3,514 | $618,291 | $171,128 |
| 2020 | 19 | 1,591 | 3,186 | $481,819 | $145,387 |
Total Patients
7,151
Total Services
13,135
Medicare Billing
$635,962
Procedure Codes
81
All Medicare Procedures & Services
81 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 11102 | Biopsy of related skin growth, first growth | Office | 2023 | 298 | 372 | $117,924 | $28,164 | 23.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 257 | 311 | $68,420 | $18,676 | 27.3% |
| 12032 | Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.6-7.5 cm | Office | 2023 | 70 | 81 | $58,725 | $18,605 | 31.7% |
| 11103 | Biopsy of related skin growth, each additional growth | Office | 2023 | 169 | 313 | $54,775 | $13,089 | 23.9% |
| 17004 | Destruction of precancer skin growth, 15 or more growths | Office | 2023 | 72 | 77 | $31,262 | $9,370 | 30.0% |
| 12052 | Intermediate repair of wound of face, ears, eyelids, nose, lips, or mouth, 2.6-5.0 cm | Office | 2023 | 31 | 36 | $23,235 | $9,070 | 39.0% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2023 | 220 | 262 | $45,850 | $8,376 | 18.3% |
| 12042 | Intermediate repair of wound of neck, hands, feet, or genitals, 2.6-7.5 cm | Office | 2023 | 21 | 25 | $15,560 | $6,188 | 39.8% |
| 11602 | Removal of cancer skin growth of body, arms, or legs, 1.1-2.0 cm | Office | 2023 | 47 | 57 | $29,925 | $5,921 | 19.8% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2023 | 176 | 1,059 | $37,065 | $5,678 | 15.3% |
| 11642 | Removal of cancer skin growth of face, ears, eyelids, nose, lips, or mouth, 1.1-2.0 cm | Office | 2023 | 33 | 42 | $25,452 | $4,712 | 18.5% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 87 | 105 | $15,750 | $4,186 | 26.6% |
| 11622 | Removal of cancer skin growth of scalp, neck, hands, feet, or genitals, 1.1-2.0 cm | Office | 2023 | 26 | 33 | $17,127 | $3,474 | 20.3% |
| 99202 | New patient office or other outpatient visit, 15-29 minutes | Office | 2023 | 66 | 66 | $13,200 | $2,949 | 22.3% |
| 11603 | Removal of cancer skin growth of body, arms, or legs, 2.1-3.0 cm | Office | 2023 | 17 | 18 | $8,892 | $2,084 | 23.4% |
| 88305 | Pathology examination of tissue using a microscope, intermediate complexity | Office | 2023 | 58 | 74 | $10,600 | $1,937 | 18.3% |
| 67810 | Biopsy of eyelid | Office | 2023 | 12 | 13 | $5,200 | $1,769 | 34.0% |
| 11104 | Punch biopsy, first skin growth | Office | 2023 | 16 | 17 | $5,372 | $1,621 | 30.2% |
| 69100 | Biopsy of ear | Office | 2023 | 30 | 30 | $7,682 | $1,315 | 17.1% |
| 11402 | Removal of noncancer skin growth of body, arms, or legs, 1.1-2.0 cm | Office | 2023 | 11 | 11 | $3,979 | $832.77 | 20.9% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2022 | 302 | 391 | $123,947 | $29,641 | 23.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 285 | 349 | $76,780 | $20,935 | 27.3% |
| 12032 | Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.6-7.5 cm | Office | 2022 | 71 | 87 | $60,183 | $19,071 | 31.7% |
| 11103 | Biopsy of related skin growth, each additional growth | Office | 2022 | 150 | 276 | $46,180 | $11,606 | 25.1% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2022 | 293 | 353 | $61,775 | $11,519 | 18.6% |
About Dr. Andrew Pitt, MD
Dr. Andrew Pitt, MD is a Dermatology healthcare provider based in Lake Oswego, Oregon. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/28/2006. The National Provider Identifier (NPI) number assigned to this provider is 1275699118.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Andrew Pitt, MD has received a total of $9,643 in payments from pharmaceutical and medical device companies, with $2,018 received in 2024. These payments were reported across 533 transactions from 29 companies. The most common payment nature is "Food and Beverage" ($9,297).
As a Medicare-enrolled provider, Pitt has provided services to 7,151 Medicare beneficiaries, totaling 13,135 services with total Medicare billing of $635,962. Data is available for 4 years (2020–2023), covering 81 distinct procedure/service records.
Ad
Practice Information
- Specialty Dermatology
- Location Lake Oswego, OR
- Active Since 12/28/2006
- Last Updated 01/23/2008
- Taxonomy Code 207N00000X
- Entity Type Individual
- NPI Number 1275699118
Products in Payments
- SKYRIZI (Biological) $1,121
- TALTZ (Drug) $1,082
- TREMFYA (Drug) $1,029
- COSENTYX (Biological) $751.19
- EUCRISA (Drug) $617.28
- Otezla (Drug) $451.43
- DUPIXENT (Biological) $391.63
- Humira (Biological) $380.73
- RINVOQ (Biological) $335.75
- Tremfya (Drug) $313.65
- HUMIRA (Biological) $251.82
- Sotyktu (Drug) $234.19
- ILUMYA (Biological) $191.54
- Bimzelx (Biological) $176.74
- VALCHLOR (Drug) $148.72
- COSENTYX (Drug) $134.76
- STELARA (Biological) $129.66
- EPIDUO FORTE (Drug) $111.87
- REMICADE (Biological) $107.57
- QBREXZA (Drug) $96.46
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.